This lecture introduces the sphingosine-1-phosphate (S1P) system as a complex, tightly regulated lipid-signaling pathway with relevance beyond Multiple Sclerosis, extending into vascular biology and other neurological diseases. The speaker explains how S1P is produced and transported, how it acts both intracellularly and via surface receptors, and why its biological effects depend on compartment, binding proteins, and the balance between pro-apoptotic ceramide and pro-survival S1P. The talk also links S1P dysregulation to disease mechanisms and emerging research questions, including biomarkers and long-term effects of S1P receptor modulation.
Key Insights from the Lecture:
- S1P is a lipid-derived signaling molecule generated from membrane sphingolipids; it is regulated by kinases, phosphatases (reversible control), and lyase activity (irreversible degradation).
- Intracellular balance matters: ceramide is described as more pro-apoptotic, while S1P supports proliferation/survival, making the ceramide-S1P ratio biologically meaningful.
- Compartmentalization is key: S1P can act inside the cell as a second messenger (e.g., calcium mobilization, survival) and outside the cell via receptor binding and downstream signaling after internalization.
- Blood vs CSF gradients: circulating S1P is relatively high in blood and mostly protein-bound (albumin/HDL), while CSF concentrations are much lower and may reflect CNS-resident sources (astrocytes, neurons, oligodendrocytes, choroid plexus/endothelium).
- Vascular relevance: S1P signaling is closely linked to endothelial barrier function and vascular tone, with connections to hypertension, stroke, and edema-related processes.
- Neuroimmunology link in MS: CSF S1P is described as increased in Multiple Sclerosis and associated with blood–brain barrier dysfunction and disease activity; S1P receptor modulators’ clinical efficacy supports a functional role of this pathway in MS.
- Practical research limitations: measuring S1P requires specialized techniques (e.g., HPLC), limiting widespread biomarker work.
- Fingolimod and biology readouts: the speaker presents data suggesting S1P levels decrease after several months of fingolimod, potentially reflecting reduced inflammation.
- Newer S1P modulators may differ immunologically: real-world observations (e.g., during the COVID period) suggest improved antibody responses with second-generation S1P modulators compared with fingolimod, implying class heterogeneity.
“Sphingosine system – pathology and pathway “.
Please subscribe to watch.
About the speaker:
Tjalf Ziemssen
Professor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden
Tjalf Ziemssen, MD, is Professor of Clinical Neuroscience in the Department of Neurology, Head of the Multiple Sclerosis Center and Neuroimmunological Laboratory, and Director of the Division of Neurometabolism at University Clinic Carl-Gustav Carus in Dresden, Germany. He earned his medical degree from the University of Bochum, Germany, and completed his neurology residency from University Hospital of Dresden, and neurobiology fellowship from Max-Planck-Institute of Neurobiology in Martinsried, Germany.
His research is focused on exploring the complex interaction between the neuroendocrinology system and the immune system and psychiatric symptoms, with a particular emphasis on stress in patients with obesity and depression and its pathologic influence on cardiovascular function using animal experimental and clinical approaches.
Dr Ziemssen has authored several articles that have been published in peer-reviewed journals including BMC Neurology, Heart Vessels, Psychoneuroendocrinology, and Annals of Neurology. He is a member of the German Neurological Society, European Neurological Society, and American Academy of Neurology.
Media
Details
We value your opinion.
